{
  "abstract": "Introduction: Autoantibodies neutralizing type I interferon (AAN-I-IFN) have been found in at least 10-15% of critical COVID-19 pneumonia cases in various studies across North and Latin America, Oceania, Europe, and Asia. We sought to analyze the prevalence of AAN-I-IFN and describe the demographic, clinical, and laboratory characteristics in a Moroccan cohort of patients with life-threatening COVID-19. Methods: We performed a cross-sectional and multicenter study of patients hospitalized in different university hospitals and clinical centers in Casablanca between November 2020 and December 2021. Results: Our cohort included 195 patients with proven SARS-CoV-2 infection, 164 (84.1%) of whom developed severe or critical COVID-19 disease requiring hospitalization, and 31 (15.9%) patients developed mild or moderate disease. Patients with moderate or mild COVID-19 did not exhibit detectable levels of AAN-I-IFNs. Among the 20 patients with AAN-I-IFN, most were men (n=16, 80%), and age ranged from 19 to 101 years. 13 (65%) patients with severe COVID-19 and 7 (35%) with critical COVID-19 had AAN-I-IFNs. Twelve patients (60%) had autoantibodies (auto-Abs) neutralizing both high and low concentrations of IFN-α2 and/or IFN-ω, five (25%) had auto-Abs neutralizing only low concentrations of IFN-α2 or IFN-ω, two (10%) had auto-Abs neutralizing IFN-β (1ng/mL) only, and one (5%) had auto-Abs neutralizing high and low concentrations of IFN-α2 and IFN-ω, as well as IFN-β at 1ng/mL, but none neutralized IFN-β at 10 ng/mL. Conclusion: Overall, AAN-I-IFNs were detected in 20/195 (10.3%) of Moroccan patients with life-threatening COVID-19 and in 20/164 (12.2%) patients with severe or critical disease, whereas none were detected in patients with mild or moderate COVID-19.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 26,
  "authors": [
    {
      "name": "Halima Kholaiq"
    },
    {
      "name": "Adrian Gervais"
    },
    {
      "name": "Paul Bastard"
    },
    {
      "name": "Hind Ouair"
    },
    {
      "name": "Lucy Bizien"
    },
    {
      "name": "Amyrath Géraldo"
    },
    {
      "name": "Fatima Ailal"
    },
    {
      "name": "Ibtihal Benhsaien"
    },
    {
      "name": "Assiya El Kettani"
    },
    {
      "name": "Ouissal Aissaoui"
    },
    {
      "name": "Naima Amenzoui"
    },
    {
      "name": "Chafik El Kettani El Hamidi"
    },
    {
      "name": "Boubaker Charra"
    },
    {
      "name": "Maha Soussi Abdallaoui"
    },
    {
      "name": "Rachid Al Harrar"
    },
    {
      "name": "Lahoucine Barrou"
    },
    {
      "name": "Mohamed Benghanem Gharbi"
    },
    {
      "name": "Moulay Hicham Afif"
    },
    {
      "name": "Qian Zhang"
    },
    {
      "name": "Laurent Abel"
    },
    {
      "name": "Aurélie Cobat"
    },
    {
      "name": "Anne Puel"
    },
    {
      "name": "Emmanuelle Jouanguy"
    },
    {
      "name": "Jean-Laurent Casanova"
    },
    {
      "name": "Ahmed Aziz Bousfiha"
    },
    {
      "name": "Jalila El Bakkouri"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/573gva777j5bz.bib",
  "cited_by": 1,
  "doi": "10.3389/fimmu.2026.1870598",
  "fulltext_url": null,
  "id": "573gva777j5bz",
  "issns": [
    "1664-3224",
    "1664-3224"
  ],
  "landing_url": "https://hal.science/hal-05863732v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2725|COVID-19 Clinical Research Studies"
    ]
  ],
  "openalex": "W7168292459",
  "pdf_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1870598/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-07-14",
  "publisher": "Frontiers",
  "ris": "https://research.draconitic.com/paper/573gva777j5bz.ris",
  "sources": [
    {
      "first_seen": "2026-11-14T12:20:48Z",
      "native_id": "hal-05863732",
      "source": "hal",
      "url": "https://hal.science/hal-05863732v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2725|COVID-19 Clinical Research Studies",
      "subfield": "infectious-disease"
    }
  ],
  "title": "Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19",
  "title_text": "Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19",
  "type": "peer-reviewed",
  "updated_at": "2026-11-15T12:20:47Z",
  "url": "https://research.draconitic.com/paper/573gva777j5bz",
  "venue": "Frontiers in Immunology",
  "versions": []
}